FundingWatcher
Home / Startups / Top health care startups / Health care startups that raised Series D or later / Health care startups that raised Series D or later in China

Health care startups that raised Series D or later in China

Updated 16 Nov 2026

Reset
Health care startups that raised Series D or later in China
One-time CSV
  • 166 funded companies, 131 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-health-care--series-d-plus~china-500a.csv166 rows × 18 columns
CompanyCityLast roundAmountDate
Barty MedicalHangzhouSeries D$29.5M2026-09-23
Kai MedtechMinhangSeries D$73.9M2026-07-28
VivolightNanshanquSeries E$13.9M2026-06-01
Full-Life TechnologiesShanghaiSeries D$109.0M2026-05-18
New Radiomedicine TechnologyChengduSeries E$145.4M2026-04-03
CORXEL PharmaceuticalsShanghaiSeries D$287.0M2026-01-22
Surgerii TechnologyHaidianSeries D$100.0M2025-12-31
MAXVAXShuangliuSeries D$27.4M2025-12-25

8 rows of the CSV in 5 of its 18 columns.

166
Startups
$16.9B
Total raised
21
Funded in the last 12 months
$1.3B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

20 of 166
20 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Barty Medical Barty Medical provides hospital healthcare services to patients. Health care Hangzhou Series D $29.5M 2026-09-23 $46.7M Shenzhen Guozhong Venture Capital Management, Sinowisdom, Sunz Fund 101 to 250 2015
Kai Medtech Kai Medtech markets and sells vascular intervention medical devices. Health care Minhang Series D $73.9M 2026-07-28 $105.3M Shenzhen Capital Group, Wuxi Capital, Hengxu Capital +1 51 to 100 2019
Vivolight Vivolight conducts medical research and develops intravascular interventional imaging technology. Biotech Nanshanqu Series E $13.9M 2026-06-01 $52.2M CAS Star, TusStar 51 to 100 2012
Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
Surgerii Technology Surgerii Technology develops minimally invasive surgical robots. Hardware Haidian Series D $100.0M 2025-12-31 $100.0M Shunwei Capital, SDIC Venture Capital, Shanghai Biomedical Industrial Equity Investment Fund +1 11 to 50 2014
MAXVAX MAXVAX develops and commercializes novel vaccines. Biotech Shuangliu Series D $27.4M 2025-12-25 $284.2M IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 251 to 500 2016
METiS Pharmaceuticals METiS Pharmaceuticals is an AI-driven drug formulation company. Artificial intelligence Hangzhou Series D $55.7M 2025-08-04 $391.7M Source Code Capital, Frees Fund, Luminous Ventures (former Lightspeed China Partners) 51 to 100 2020
Weimai Weimai uses big data and artificial intelligence to digitize its healthcare service platform. Artificial intelligence Yuhang Series D $27.3M 2025-01-07 $257.3M IDG Capital, Matrix Partners China, Source Code Capital +1 101 to 250 2013
IMPACT Therapeutics IMPACT Therapeutics develops similar drugs to treat cancer. Biotech Nanjing Series D $34.6M 2024-11-15 BioVenture, Lilly Asia Ventures, Decheng Capital +2 51 to 100 2009
DK MedTech DK MedTech manufactures vascular interventional medical device products. Health care Suzhou Series E $24.5M 2024-06-21 $36.2M Qiming Venture Partners, Legend Capital, Oriza Seed Capital (Oriza Yuandian) +1 251 to 500 2015
Yidao Biotechnology Yidao Biotechnology researches and develops vaccines and biomedical products. Biotech Suzhou Series D $25.2M 2024-05-09 Qiming Venture Partners, Northern Light Venture Capital 2017
Atom Bioscience & Pharmaceutical Atom Bioscience is a clinical-stage biotechnology company. Biotech Suzhou Series D $82.1M 2023-10-16 Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 11 to 50 2012
Landing Medical High Technology Landing Medical High Technology develops AI-driven diagnostic technology for cervical cancer screening. Artificial intelligence Wuhan Series D $50.1M 2021-11-10 $50.1M China Merchants Venture Capital, Dalton Venture, Sangel Capital 251 to 500 2000
Shukun Technology Shukun Technology develops AI diagnostic systems for chronic diseases in China. Artificial intelligence Beijing Series D $105.8M 2021-08-17 $296.4M Qiming Venture Partners, Goldman Sachs, 5Y Capital +1 501 to 1,000 2017
Infervision Infervision uses deep learning and computer vision to help diagnose cancers. Artificial intelligence Beijing Series D $140.0M 2021-07-23 $214.7M Sequoia Capital, Qiming Venture Partners, CDH Investments +1 51 to 100 2015
Supermonkey Supermonkey develops and operates a mobile app that provides fitness services. Health care Shenzhen Series E $15.5M 2021-05-06 CICC, PreAngel, Fosun RZ Capital +1 51 to 100 2014
Keep Unicorn Keep is a mobile fitness community offering training programs for different groups of people. Education Beijing Series F $360.0M 2021-01-10 Goldman Sachs, Hillhouse Investment, Coatue +1 501 to 1,000 2014
DXY Unicorn DXY is an online healthcare community connecting doctors, consumers, and healthcare organizations. Biotech Hangzhou Series E $500.0M 2020-12-29 $682.0M Shunwei Capital, DCM Ventures, Legend Capital +1 101 to 250 2000

Table 1. Health care startups that raised Series D or later in China: the 20 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 166.

Largest rounds

Last 12 months
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
2 New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
3 Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
4 Surgerii Technology Surgerii Technology develops minimally invasive surgical robots. Hardware Haidian Series D $100.0M 2025-12-31 $100.0M Shunwei Capital, SDIC Venture Capital, Shanghai Biomedical Industrial Equity Investment Fund +1 11 to 50 2014
5 Kai Medtech Kai Medtech markets and sells vascular intervention medical devices. Health care Minhang Series D $73.9M 2026-07-28 $105.3M Shenzhen Capital Group, Wuxi Capital, Hengxu Capital +1 51 to 100 2019
6 Barty Medical Barty Medical provides hospital healthcare services to patients. Health care Hangzhou Series D $29.5M 2026-09-23 $46.7M Shenzhen Guozhong Venture Capital Management, Sinowisdom, Sunz Fund 101 to 250 2015
7 MAXVAX MAXVAX develops and commercializes novel vaccines. Biotech Shuangliu Series D $27.4M 2025-12-25 $284.2M IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 251 to 500 2016
8 Vivolight Vivolight conducts medical research and develops intravascular interventional imaging technology. Biotech Nanshanqu Series E $13.9M 2026-06-01 $52.2M CAS Star, TusStar 51 to 100 2012

Table 2. Health care startups that raised Series D or later in China: the 8 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 6 4%
2 Matrix Partners China Venture capital firm Beijing, China 4 2%
3 Shenzhen Capital Group Venture capital firm Nanshan, China 3 2% 2 Kai Medtech, MAXVAX
4 IDG Capital Private equity firm Beijing, China 3 2% 1 MAXVAX
5 CICC Investment bank Beijing, China 3 2%
6 Source Code Capital Venture capital firm Chaoyang, China 3 2%
7 BioVenture Venture capital firm Suzhou, China 3 2%
8 Eight Roads Ventures Venture capital firm London, United Kingdom 3 2%
9 CDH Investments Private equity firm Kowloon City, Hong Kong 3 2%
10 Northern Light Venture Capital Venture capital firm Beijing, China 3 2%
11 5Y Capital Venture capital firm Xuhui, China 3 2%
12 Sinowisdom Venture capital firm Hangzhou, China 2 1% 1 Barty Medical
13 Ventech China Corporate venture arm Shanghai, China 2 1% 1 Huamei Haolian
14 Shanghai Biomedical Industrial Equity Investment Fund Venture capital firm Huangpu, China 2 1% 1 Surgerii Technology
15 Shunwei Capital Venture capital firm Beijing, China 2 1% 1 Surgerii Technology

Table 3. Health care startups that raised Series D or later in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 66 40% $6.6B
Software 23 14% $2.7B
Hardware 9 5% $213.8M
Artificial intelligence 9 5% $1.3B
Fintech 4 2% $631.7M
Commerce 3 2% $279.3M
Education 2 1%

Table 4. Health care startups that raised Series D or later in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series D+ 166 100% $46.2M

Table 5. Health care startups that raised Series D or later in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Beijing 37 22%
Shanghai 30 18%
Hangzhou 12 7%
Suzhou 12 7%
Shenzhen 10 6%
Haidian 6 4%
Guangzhou 6 4%
Minhang 4 2%
Chengdu 4 2%
Daxing 3 2%
Nanjing 3 2%
Changzhou 2 1%

Table 6. Health care startups that raised Series D or later in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
September 2026 5 24% $283.0M
July 2026 2 10% $110.8M
June 2026 2 10% $60.8M
May 2026 1 5% $109.0M
April 2026 3 14% $274.6M
March 2026 1 5%
January 2026 2 10% $294.7M
December 2025 5 24% $194.8M

Table 7. Health care startups that raised Series D or later in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 16 10% $1.1B
2025 22 13% $646.1M
2024 14 8% $151.8M
2023 13 8% $473.7M
2022 14 8% $518.9M
2021 30 18% $3.4B

Table 8. Health care startups that raised Series D or later in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 3 2%
2015 to 2019 56 34%
2010 to 2014 66 40%
Before 2010 41 25%

Table 9. Health care startups that raised Series D or later in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 3 2%
11 to 50 33 20%
51 to 100 38 23%
101 to 250 29 18%
251 to 500 21 13%
501 to 1,000 21 13%
1,001 to 5,000 14 9%
5,001 to 10,000 2 1%
10,001 or more 1 1%

Table 10. Health care startups that raised Series D or later in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many health care startups in China whose last round is Series D or later are on the list?
166, in the file dated 16 November 2026. 21 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 166 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Health care startups that raised Series D or later in China: 166 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Health care at other stages in China

Other sectors that raised Series D or later in China

Cite: FundingWatcher, 166 health care companies in China whose most recent round is Series D or later, 16 November 2026. https://fundingwatcher.com/startups/health-care/series-d-plus/china-500a/